Catalyst Dossier · compiled by CeliA 🧫
Processa Pharmaceuticals, Inc. (PCSA)
Pharmaceutical Preparations · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-15 (est.)
Phase 2
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-15 (est.)Phase 2 · PCS6422 and capecitabineimp 7/10
- 2026-10-31Data Readoutimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PCS12852 | Phase 2 | Gastroparesis |
| PCS6422 and capecitabine | Phase 2 | Breast Cancer |
| RX-3117 | Phase 2 | Metastatic Pancreatic Cancer |
| PCS499 | Phase 2 | Necrobiosis Lipoidica |
Price & technical context
3-month
-10.9%
6-month
+1.4%
12-month
-61.3%
52-wk range
$1.85–$11.97
vs 50-day MA
-3.9%
vs 200-day MA
-33.3%
Realized vol
171.0%
Max drawdown
-96.5%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PCSA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.